Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A 52-Year-Old Lupus Paper Remains Important Today

Ruth Jessen Hickman, MD  |  Issue: December 2020  |  December 14, 2020

Dr. Pisetsky

Dr. Pisetsky

Dr. Pisetsky says a variety of assays then existed that could be used to measure anti-DNA. “We’re going back a long time ago, so the techniques were much more crude than those available today. Nevertheless, it was possible to come up with an effective quantitative assay.”

Dr. Schur performed all the assays himself. Using the Ouchterlony immunodiffusion technique, Dr. Schur identified serum antibodies to various forms of DNA (as well as free DNA) and antibodies to some other nuclear proteins. He also assessed the presence of antibodies to DNA that fixed complement. Additionally, Dr. Schur measured the total serum hemolytic complement, using a bioassay designed to assess the hemolytic potential of the complement system.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Schur explains that most people now just measure two components of the comple­ment system, C3 and C4, but good assays for those complement proteins were not available at the time. Instead, he used a test known as CH50. While at Walter Reed, he had learned how to do this test, which assesses the entire complement system. Dr. Schur explains that this technique was more sensitive than another one then commonly used to assess the complement system, the Kabat technique.

Dr. Schur and Dr. Sandson found that most, though not all, of the patients with high titers of complement-fixing antibodies to DNA had active renal disease. Not all of the patients who had very low complement levels had active renal disease. But all of the patients who had both high amounts of complement-fixing antibodies to DNA and low serum complement levels had active renal disease. Only 13% of patients with active renal disease had no anti-DNA antibodies and normal complement.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Schur notes that it recently had been shown that lupus nephritis patients typically had high anti-DNA and low complement levels.6 That pattern was confirmed in this paper, but a new predictive element was revealed as well.

In the paper, Dr. Schur and Dr. Sandson provided a brief case study of a 17-year-old girl with lupus nephritis, J.B. In the article, they tracked her clinical course and laboratory findings and displayed them graphically.

“A pattern began to evolve—it’s shown in Figure 1 as sort of a typical patient,” says Dr. Schur. “As levels of antibody to DNA increased and complement levels diminished, it often preceded a clinical flare. And if you treated them—which at the time was steroids and immunosuppressives—the anti-DNA levels went down and the complement levels went up.”

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Dr. Peter SchurLost & Found

Related Articles
    Biophoto Associates / ScienceSource.com

    Dr. Peter Schur Discusses Lupus Treatment, Management Advances in Past 50 Years

    June 13, 2017

    Although systemic lupus erythematosus still does not have a definite cause or cure, rheumatologists and researchers over the past 50 years have witnessed and contributed to a great deal of progress that helps patients, says Peter H. Schur, MD, director emeritus of the Lupus Center, Brigham and Women’s Hospital, and professor, Harvard Medical School, Boston. Dr. Schur’s…

    How a Nuclear Molecule Alarms the Immune System

    August 1, 2011

    The role of HMGB1 in the pathogenesis of lupus nephritis

    Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

    December 1, 2014

    A review of data on antinuclear antibodies and tests for rheumatoid arthritis

    Exploring the Complement System in Human Disease

    February 1, 2010

    Novel disease associations revealed by whole genome screens

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences